Neuropathy is a well known side effect of vincristine, however cranial nerve toxicities are reported less frequently which can involve any cranial nerve in mostly bilateral pattern. As many patients have primary tumors or metastatic lesions in sites that could cause the clinician to overlook this reversible cause of neurologic dysfunction, the potential for misdiagnosis is high. Here, along wit...

Vincristine (VCR) is a vinca alkaloid that is used for treatment of many malignancies. The vinca alkaloids are neurotoxic, usually causing a peripheral neuropathy, but cranial neuropathies are rare as side effects. Described here is the case of a 2.5-year-old boy, a known case of Wilms' tumor, treated by vincristine (0.067 mg/kg/day) and dactinomycin (0.045 mg/kg/day) after surgery. Three weeks...

The efficacy and safety of intraperitoneal administration of vincristine sulphate was determined in mice bearing Ehrlich ascitic carcinoma. The tumor bearing animals were administered with 0.5 mg/kg body weight (b.wt) of freshly prepared vincristine sulphate intraperitoneally on day 6 after tumor transplantation followed by drug administration once daily 5 days a week consecutively. The observa...

TAKANO, S. Difference in Effects o f Vinblastine and V incristine on the Dog Platelet Aggregation. Tohoku J. exp. Med., 1981, 135 (1), 79-85 The present study was attempted to determine difference in effects of vinblastine and vincristine on ADP-induced aggregation of dog platelets. Vinblastine manifested biphasic influence depending upon concentrations, i.e., in low concentrations (0.2-20 ,ug/...

A single i.p. injection of vincristine (1000 microgram/kg) into rats increased the plasma concentration of corticosterone after a latent period of 4 hr; the effect lasted for 48 hr. The response was dose related with the threshold dose being 100 microgram/kg and the maximal effect occurring after 250 microgram/kg. Vincristine also increased plasma corticosterone levels in hypophysectomized rats...

Use of the conventional cancer chemotherapy (i.e. vincristine) is limited in tumor cells exhibiting pre-existing or acquired resistance. Here, we found that C6 ceramide (C6) dramatically sensitized vincristine’s activity. In vitro, C6 and vincristine coadministration induced substantial necrosis and apoptosis in multiple human cancer cell lines, which were accompanied by a profound AMP-activate...

By means of time-lapse microcinematography, metaphase arrest was studied in synchronized NHIK 3025 cells in contact with 5-chloropyrimidin-2-one (NY 3000) or vincristine. A dose-dependent prolongation of mitosis was found for both substances, and the fraction of cells able to escape mitotic arrest declined gradually as the concen tration of NY 3000 or vincristine was increased. Significant prol...

Vincristine and vinblastine exhibit differential activity against tumors and normal tissues. In this work, a number of cultured cell lines were assayed for their sensitivity to the antiproliferative and cytotoxic effects of the two drugs following short-term (4 hr) or during continuous exposures. Differential activity was not seen when cells were subjected to continuous exposures. The concentra...

Vincristine sensitive (L1210) and resistant (L1210/VCR) L1210 mouse leukemia cells were studied from morphological and histochemical point of view. The morphological and histochemical findings reflected differences in membrane structure and in physiological state of sensitive and resistant cells. Numerous villous projections and cytoplasmic protrusions of the cell surface as well as higher acti...

Differential toxicity of vincristine and vinblastine against cells of a cloned subline of human promyelocytic leukemia (HL-60/CI) was dependent on exposure conditions. During continuous ex posures of 48 h, vincristine and vinblastine were equitoxic with drug concentrations that inhibited proliferation rates by 50% of 7.6 and 8.1 nw, respectively. When cells were subjected to 4-h exposures and t...